nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP1A2—Pentoxifylline—systemic scleroderma	0.0623	0.243	CbGbCtD
Thalidomide—CYP1A2—Leflunomide—systemic scleroderma	0.0594	0.232	CbGbCtD
Thalidomide—CYP2C9—Leflunomide—systemic scleroderma	0.0536	0.209	CbGbCtD
Thalidomide—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0493	0.192	CbGbCtD
Thalidomide—CYP2C19—Prednisone—systemic scleroderma	0.0318	0.124	CbGbCtD
Thalidomide—CYP2C9—cardial valve—systemic scleroderma	0.0187	0.207	CbGeAlD
Thalidomide—PTGS2—skeletal joint—systemic scleroderma	0.00585	0.0646	CbGeAlD
Thalidomide—NFKB1—connective tissue—systemic scleroderma	0.00428	0.0474	CbGeAlD
Thalidomide—FGFR2—connective tissue—systemic scleroderma	0.00322	0.0356	CbGeAlD
Thalidomide—NFKB1—digestive system—systemic scleroderma	0.00309	0.0342	CbGeAlD
Thalidomide—NFKB1—tendon—systemic scleroderma	0.00295	0.0325	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—systemic scleroderma	0.00294	0.0325	CbGeAlD
Thalidomide—FGFR2—skin of body—systemic scleroderma	0.00291	0.0321	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00269	0.624	CbGdCrCtD
Thalidomide—CRBN—digestive system—systemic scleroderma	0.00259	0.0287	CbGeAlD
Thalidomide—NFKB1—lung—systemic scleroderma	0.00258	0.0286	CbGeAlD
Thalidomide—PTGS1—artery—systemic scleroderma	0.00256	0.0283	CbGeAlD
Thalidomide—CRBN—tendon—systemic scleroderma	0.00247	0.0273	CbGeAlD
Thalidomide—PTGS2—artery—systemic scleroderma	0.00245	0.0271	CbGeAlD
Thalidomide—FGFR2—digestive system—systemic scleroderma	0.00232	0.0257	CbGeAlD
Thalidomide—CRBN—lung—systemic scleroderma	0.00217	0.0239	CbGeAlD
Thalidomide—PTGS1—endothelium—systemic scleroderma	0.00216	0.0239	CbGeAlD
Thalidomide—PTGS2—endothelium—systemic scleroderma	0.00207	0.0229	CbGeAlD
Thalidomide—PTGS1—blood vessel—systemic scleroderma	0.002	0.0221	CbGeAlD
Thalidomide—FGFR2—lung—systemic scleroderma	0.00194	0.0215	CbGeAlD
Thalidomide—PTGS2—blood vessel—systemic scleroderma	0.00191	0.0211	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00162	0.376	CbGdCrCtD
Thalidomide—CYP1A1—skin of body—systemic scleroderma	0.00105	0.0116	CbGeAlD
Thalidomide—CYP2C19—digestive system—systemic scleroderma	0.00104	0.0115	CbGeAlD
Thalidomide—PTGS1—connective tissue—systemic scleroderma	0.00102	0.0113	CbGeAlD
Thalidomide—PTGS2—connective tissue—systemic scleroderma	0.000978	0.0108	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—systemic scleroderma	0.000936	0.0103	CbGeAlD
Thalidomide—PTGS1—skin of body—systemic scleroderma	0.000924	0.0102	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—systemic scleroderma	0.000895	0.00989	CbGeAlD
Thalidomide—PTGS2—skin of body—systemic scleroderma	0.000883	0.00976	CbGeAlD
Thalidomide—CYP1A2—digestive system—systemic scleroderma	0.000853	0.00942	CbGeAlD
Thalidomide—CYP1A1—digestive system—systemic scleroderma	0.000841	0.0093	CbGeAlD
Thalidomide—CYP3A5—digestive system—systemic scleroderma	0.000822	0.00909	CbGeAlD
Thalidomide—CYP2C9—digestive system—systemic scleroderma	0.000809	0.00895	CbGeAlD
Thalidomide—CYP2E1—digestive system—systemic scleroderma	0.000767	0.00848	CbGeAlD
Thalidomide—PTGS1—digestive system—systemic scleroderma	0.000739	0.00817	CbGeAlD
Thalidomide—CYP2E1—tendon—systemic scleroderma	0.00073	0.00807	CbGeAlD
Thalidomide—CYP1A2—lung—systemic scleroderma	0.000712	0.00787	CbGeAlD
Thalidomide—PTGS2—digestive system—systemic scleroderma	0.000706	0.00781	CbGeAlD
Thalidomide—PTGS1—tendon—systemic scleroderma	0.000703	0.00777	CbGeAlD
Thalidomide—CYP1A1—lung—systemic scleroderma	0.000703	0.00776	CbGeAlD
Thalidomide—CYP3A5—lung—systemic scleroderma	0.000687	0.00759	CbGeAlD
Thalidomide—PTGS2—tendon—systemic scleroderma	0.000672	0.00743	CbGeAlD
Thalidomide—CYP2E1—lung—systemic scleroderma	0.000641	0.00708	CbGeAlD
Thalidomide—PTGS1—lung—systemic scleroderma	0.000617	0.00682	CbGeAlD
Thalidomide—PTGS2—lung—systemic scleroderma	0.00059	0.00652	CbGeAlD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000518	0.00278	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000514	0.00275	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.000509	0.00273	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000509	0.00273	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000501	0.00269	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000488	0.00262	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.000481	0.00258	CbGpPWpGaD
Thalidomide—TNF—Monoamine Transport—IL1B—systemic scleroderma	0.000479	0.00257	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000477	0.00256	CbGpPWpGaD
Thalidomide—TNF—Matrix Metalloproteinases—MMP9—systemic scleroderma	0.000476	0.00255	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000474	0.00254	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000471	0.00252	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.00047	0.00252	CbGpPWpGaD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—IL1A—systemic scleroderma	0.000466	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—CCL2—systemic scleroderma	0.000465	0.00249	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL1A—systemic scleroderma	0.000456	0.00245	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—MMP2—systemic scleroderma	0.000453	0.00243	CbGpPWpGaD
Thalidomide—TNF—amb2 Integrin signaling—MMP9—systemic scleroderma	0.000452	0.00242	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000449	0.00241	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000449	0.00241	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL1A—systemic scleroderma	0.000446	0.00239	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—BLK—systemic scleroderma	0.000444	0.00238	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—CD40LG—systemic scleroderma	0.000444	0.00238	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000442	0.00237	CbGpPWpGaD
Thalidomide—TNF—IL27-mediated signaling events—TGFB1—systemic scleroderma	0.00044	0.00236	CbGpPWpGaD
Thalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.00044	0.00236	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000435	0.00234	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000433	0.00232	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000427	0.00229	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL1B—systemic scleroderma	0.000427	0.00229	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—TGFB1—systemic scleroderma	0.000427	0.00229	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.000422	0.00227	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—BLK—systemic scleroderma	0.000421	0.00226	CbGpPWpGaD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.000421	0.00226	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000414	0.00222	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000412	0.00221	CbGpPWpGaD
Thalidomide—NFKB1—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000408	0.00219	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.000396	0.00212	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.000394	0.00212	CbGpPWpGaD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000394	0.00211	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000389	0.00209	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—IL1B—systemic scleroderma	0.000381	0.00204	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000376	0.00201	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—NOS3—systemic scleroderma	0.000374	0.00201	CbGpPWpGaD
Thalidomide—FGFR2—FGF signaling pathway—MMP9—systemic scleroderma	0.00037	0.00199	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000369	0.00198	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000364	0.00195	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000359	0.00193	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000359	0.00192	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000357	0.00191	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—CCL2—systemic scleroderma	0.000354	0.0019	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—IL1B—systemic scleroderma	0.000353	0.00189	CbGpPWpGaD
Thalidomide—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.00035	0.00188	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—MMP9—systemic scleroderma	0.000341	0.00183	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.00034	0.00182	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000333	0.00178	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.00033	0.00177	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL1A—systemic scleroderma	0.000324	0.00174	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.000322	0.00173	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.00032	0.00172	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—IL1B—systemic scleroderma	0.000318	0.00171	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000318	0.0017	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000317	0.0017	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000301	0.00161	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—IL1A—systemic scleroderma	0.000295	0.00158	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000295	0.00158	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000281	0.00151	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.00028	0.0015	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000279	0.00149	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000275	0.00148	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000272	0.00146	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—IL1B—systemic scleroderma	0.000269	0.00144	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000268	0.00144	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—RHOB—systemic scleroderma	0.000266	0.00143	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—CTGF—systemic scleroderma	0.000265	0.00142	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	0.000259	0.00139	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000259	0.00139	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000249	0.00134	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.000245	0.00131	CbGpPWpGaD
Thalidomide—FGFR2—Ectoderm Differentiation—CCL2—systemic scleroderma	0.000245	0.00131	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000244	0.00131	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic scleroderma	0.000242	0.0013	CbGpPWpGaD
Thalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000242	0.0013	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL1B—systemic scleroderma	0.000238	0.00128	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—IL1B—systemic scleroderma	0.000233	0.00125	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL1B—systemic scleroderma	0.000233	0.00125	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000226	0.00121	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000224	0.0012	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL1A—systemic scleroderma	0.000223	0.0012	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—CCL2—systemic scleroderma	0.000223	0.00119	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000219	0.00118	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000214	0.00115	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000214	0.00115	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000213	0.00114	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000213	0.00114	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.00021	0.00113	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	0.000209	0.00112	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CSK—systemic scleroderma	0.000206	0.0011	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—RHOB—systemic scleroderma	0.000203	0.00109	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ITGAM—systemic scleroderma	0.000201	0.00108	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD247—systemic scleroderma	0.000201	0.00108	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	0.0002	0.00107	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000197	0.00106	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CSK—systemic scleroderma	0.000195	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000194	0.00104	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD247—systemic scleroderma	0.000193	0.00104	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ITGAM—systemic scleroderma	0.000191	0.00102	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD247—systemic scleroderma	0.000191	0.00102	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.00019	0.00102	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000189	0.00101	CbGpPWpGaD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic scleroderma	0.000185	0.00099	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	0.000183	0.000984	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD247—systemic scleroderma	0.000183	0.000984	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—TGFB1—systemic scleroderma	0.000181	0.00097	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—BLK—systemic scleroderma	0.000179	0.000959	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—TNFAIP3—systemic scleroderma	0.000179	0.000959	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	0.000178	0.000957	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	0.000178	0.000955	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000177	0.00095	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000174	0.000933	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000172	0.000923	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000172	0.000922	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—BLK—systemic scleroderma	0.00017	0.00091	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL1B—systemic scleroderma	0.000169	0.000905	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000167	0.000896	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000166	0.000892	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—MMP9—systemic scleroderma	0.000159	0.000854	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SMAD7—systemic scleroderma	0.000155	0.000832	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000153	0.00082	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000148	0.000794	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CTLA4—systemic scleroderma	0.000147	0.000786	CbGpPWpGaD
Thalidomide—Abdominal pain—Leflunomide—systemic scleroderma	0.000144	0.000312	CcSEcCtD
Thalidomide—Body temperature increased—Leflunomide—systemic scleroderma	0.000144	0.000312	CcSEcCtD
Thalidomide—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000144	0.000311	CcSEcCtD
Thalidomide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000143	0.00031	CcSEcCtD
Thalidomide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00031	CcSEcCtD
Thalidomide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00031	CcSEcCtD
Thalidomide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00031	CcSEcCtD
Thalidomide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000143	0.000309	CcSEcCtD
Thalidomide—Myocardial infarction—Prednisone—systemic scleroderma	0.000143	0.000309	CcSEcCtD
Thalidomide—Breast disorder—Methotrexate—systemic scleroderma	0.000143	0.000309	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000143	0.000309	CcSEcCtD
Thalidomide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000308	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000142	0.000308	CcSEcCtD
Thalidomide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000142	0.000308	CcSEcCtD
Thalidomide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000142	0.000307	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000307	CcSEcCtD
Thalidomide—FGFR2—Disease—TGFBI—systemic scleroderma	0.000142	0.000761	CbGpPWpGaD
Thalidomide—Insomnia—Lisinopril—systemic scleroderma	0.000142	0.000306	CcSEcCtD
Thalidomide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000141	0.000306	CcSEcCtD
Thalidomide—Paraesthesia—Lisinopril—systemic scleroderma	0.000141	0.000304	CcSEcCtD
Thalidomide—Vomiting—Captopril—systemic scleroderma	0.000141	0.000304	CcSEcCtD
Thalidomide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000303	CcSEcCtD
Thalidomide—Dyspnoea—Lisinopril—systemic scleroderma	0.00014	0.000302	CcSEcCtD
Thalidomide—Rash—Captopril—systemic scleroderma	0.000139	0.000302	CcSEcCtD
Thalidomide—Dermatitis—Captopril—systemic scleroderma	0.000139	0.000301	CcSEcCtD
Thalidomide—Somnolence—Lisinopril—systemic scleroderma	0.000139	0.000301	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CTLA4—systemic scleroderma	0.000139	0.000746	CbGpPWpGaD
Thalidomide—Headache—Captopril—systemic scleroderma	0.000138	0.0003	CcSEcCtD
Thalidomide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000299	CcSEcCtD
Thalidomide—Dyspepsia—Lisinopril—systemic scleroderma	0.000138	0.000298	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	0.000138	0.000738	CbGpPWpGaD
Thalidomide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000137	0.000297	CcSEcCtD
Thalidomide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000137	0.000297	CcSEcCtD
Thalidomide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000297	CcSEcCtD
Thalidomide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000295	CcSEcCtD
Thalidomide—Decreased appetite—Lisinopril—systemic scleroderma	0.000136	0.000294	CcSEcCtD
Thalidomide—Eosinophilia—Methotrexate—systemic scleroderma	0.000135	0.000293	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000135	0.000292	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000135	0.000724	CbGpPWpGaD
Thalidomide—Fatigue—Lisinopril—systemic scleroderma	0.000135	0.000292	CcSEcCtD
Thalidomide—Shock—Mycophenolate mofetil—systemic scleroderma	0.000135	0.000292	CcSEcCtD
Thalidomide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000135	0.000291	CcSEcCtD
Thalidomide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000134	0.000291	CcSEcCtD
Thalidomide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000134	0.00029	CcSEcCtD
Thalidomide—Pancreatitis—Methotrexate—systemic scleroderma	0.000134	0.00029	CcSEcCtD
Thalidomide—Constipation—Lisinopril—systemic scleroderma	0.000134	0.00029	CcSEcCtD
Thalidomide—Pain—Lisinopril—systemic scleroderma	0.000134	0.00029	CcSEcCtD
Thalidomide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000134	0.00029	CcSEcCtD
Thalidomide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000288	CcSEcCtD
Thalidomide—Bradycardia—Prednisone—systemic scleroderma	0.000133	0.000288	CcSEcCtD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000133	0.000714	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000287	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000132	0.000708	CbGpPWpGaD
Thalidomide—Diarrhoea—Azathioprine—systemic scleroderma	0.000132	0.000286	CcSEcCtD
Thalidomide—Nausea—Captopril—systemic scleroderma	0.000131	0.000284	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000131	0.000703	CbGpPWpGaD
Thalidomide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000283	CcSEcCtD
Thalidomide—Asthenia—Leflunomide—systemic scleroderma	0.000131	0.000283	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.00013	0.000696	CbGpPWpGaD
Thalidomide—Pancytopenia—Methotrexate—systemic scleroderma	0.00013	0.000281	CcSEcCtD
Thalidomide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000129	0.000279	CcSEcCtD
Thalidomide—Pruritus—Leflunomide—systemic scleroderma	0.000129	0.000279	CcSEcCtD
Thalidomide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000277	CcSEcCtD
Thalidomide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000128	0.000277	CcSEcCtD
Thalidomide—Neutropenia—Methotrexate—systemic scleroderma	0.000128	0.000276	CcSEcCtD
Thalidomide—Dizziness—Azathioprine—systemic scleroderma	0.000128	0.000276	CcSEcCtD
Thalidomide—TNF—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000127	0.000682	CbGpPWpGaD
Thalidomide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000127	0.000275	CcSEcCtD
Thalidomide—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000126	0.000272	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000126	0.000673	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000125	0.00027	CcSEcCtD
Thalidomide—NFKB1—Immune System—CSK—systemic scleroderma	0.000125	0.000669	CbGpPWpGaD
Thalidomide—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000125	0.00027	CcSEcCtD
Thalidomide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000125	0.00027	CcSEcCtD
Thalidomide—Diarrhoea—Leflunomide—systemic scleroderma	0.000125	0.00027	CcSEcCtD
Thalidomide—Urticaria—Lisinopril—systemic scleroderma	0.000124	0.000269	CcSEcCtD
Thalidomide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000268	CcSEcCtD
Thalidomide—Abdominal pain—Lisinopril—systemic scleroderma	0.000124	0.000268	CcSEcCtD
Thalidomide—Body temperature increased—Lisinopril—systemic scleroderma	0.000124	0.000268	CcSEcCtD
Thalidomide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000266	CcSEcCtD
Thalidomide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000123	0.000266	CcSEcCtD
Thalidomide—NFKB1—Immune System—IRF5—systemic scleroderma	0.000123	0.000658	CbGpPWpGaD
Thalidomide—Vomiting—Azathioprine—systemic scleroderma	0.000123	0.000265	CcSEcCtD
Thalidomide—Pneumonia—Methotrexate—systemic scleroderma	0.000123	0.000265	CcSEcCtD
Thalidomide—Eye disorder—Prednisone—systemic scleroderma	0.000122	0.000265	CcSEcCtD
Thalidomide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000265	CcSEcCtD
Thalidomide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000264	CcSEcCtD
Thalidomide—Drowsiness—Methotrexate—systemic scleroderma	0.000122	0.000264	CcSEcCtD
Thalidomide—Infestation NOS—Methotrexate—systemic scleroderma	0.000122	0.000264	CcSEcCtD
Thalidomide—Infestation—Methotrexate—systemic scleroderma	0.000122	0.000264	CcSEcCtD
Thalidomide—Rash—Azathioprine—systemic scleroderma	0.000122	0.000263	CcSEcCtD
Thalidomide—Dermatitis—Azathioprine—systemic scleroderma	0.000122	0.000263	CcSEcCtD
Thalidomide—Depression—Methotrexate—systemic scleroderma	0.000121	0.000263	CcSEcCtD
Thalidomide—TNF—Adipogenesis—TGFB1—systemic scleroderma	0.000121	0.000651	CbGpPWpGaD
Thalidomide—Headache—Azathioprine—systemic scleroderma	0.000121	0.000261	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000121	0.000261	CcSEcCtD
Thalidomide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000261	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000121	0.000647	CbGpPWpGaD
Thalidomide—Dizziness—Leflunomide—systemic scleroderma	0.00012	0.000261	CcSEcCtD
Thalidomide—Renal failure—Methotrexate—systemic scleroderma	0.00012	0.000259	CcSEcCtD
Thalidomide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000258	CcSEcCtD
Thalidomide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000119	0.000257	CcSEcCtD
Thalidomide—Stomatitis—Methotrexate—systemic scleroderma	0.000119	0.000257	CcSEcCtD
Thalidomide—Angiopathy—Prednisone—systemic scleroderma	0.000119	0.000257	CcSEcCtD
Thalidomide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000118	0.000256	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000256	CcSEcCtD
Thalidomide—FGFR2—Immune System—CSK—systemic scleroderma	0.000118	0.000635	CbGpPWpGaD
Thalidomide—Immune system disorder—Prednisone—systemic scleroderma	0.000118	0.000256	CcSEcCtD
Thalidomide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000254	CcSEcCtD
Thalidomide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000254	CcSEcCtD
Thalidomide—NFKB1—Immune System—CD247—systemic scleroderma	0.000117	0.000629	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ITGAM—systemic scleroderma	0.000117	0.000629	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IRF8—systemic scleroderma	0.000117	0.000629	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000117	0.000628	CbGpPWpGaD
Thalidomide—Arrhythmia—Prednisone—systemic scleroderma	0.000117	0.000253	CcSEcCtD
Thalidomide—Sweating—Methotrexate—systemic scleroderma	0.000117	0.000253	CcSEcCtD
Thalidomide—FGFR2—Immune System—IRF5—systemic scleroderma	0.000116	0.000624	CbGpPWpGaD
Thalidomide—Haematuria—Methotrexate—systemic scleroderma	0.000116	0.000251	CcSEcCtD
Thalidomide—Vomiting—Leflunomide—systemic scleroderma	0.000116	0.000251	CcSEcCtD
Thalidomide—Alopecia—Prednisone—systemic scleroderma	0.000116	0.00025	CcSEcCtD
Thalidomide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000115	0.00025	CcSEcCtD
Thalidomide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000115	0.000249	CcSEcCtD
Thalidomide—Epistaxis—Methotrexate—systemic scleroderma	0.000115	0.000249	CcSEcCtD
Thalidomide—Rash—Leflunomide—systemic scleroderma	0.000115	0.000249	CcSEcCtD
Thalidomide—Dermatitis—Leflunomide—systemic scleroderma	0.000115	0.000248	CcSEcCtD
Thalidomide—Mental disorder—Prednisone—systemic scleroderma	0.000115	0.000248	CcSEcCtD
Thalidomide—Nausea—Azathioprine—systemic scleroderma	0.000115	0.000248	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000114	0.000614	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SMAD7—systemic scleroderma	0.000114	0.000614	CbGpPWpGaD
Thalidomide—Headache—Leflunomide—systemic scleroderma	0.000114	0.000247	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CD40LG—systemic scleroderma	0.000114	0.000611	CbGpPWpGaD
Thalidomide—Malnutrition—Prednisone—systemic scleroderma	0.000114	0.000246	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000114	0.000246	CcSEcCtD
Thalidomide—FGFR2—Disease—HSPG2—systemic scleroderma	0.000113	0.000607	CbGpPWpGaD
Thalidomide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000245	CcSEcCtD
Thalidomide—Asthenia—Lisinopril—systemic scleroderma	0.000112	0.000243	CcSEcCtD
Thalidomide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000243	CcSEcCtD
Thalidomide—FGFR2—Immune System—ITGAM—systemic scleroderma	0.000111	0.000597	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IRF8—systemic scleroderma	0.000111	0.000597	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD247—systemic scleroderma	0.000111	0.000597	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000111	0.000595	CbGpPWpGaD
Thalidomide—Pruritus—Lisinopril—systemic scleroderma	0.000111	0.00024	CcSEcCtD
Thalidomide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000111	0.000239	CcSEcCtD
Thalidomide—NFKB1—Immune System—TNFAIP3—systemic scleroderma	0.00011	0.000589	CbGpPWpGaD
Thalidomide—Rash—Mycophenolic acid—systemic scleroderma	0.00011	0.000237	CcSEcCtD
Thalidomide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000109	0.000237	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—systemic scleroderma	0.000109	0.000237	CcSEcCtD
Thalidomide—FGFR2—Disease—CSK—systemic scleroderma	0.000109	0.000586	CbGpPWpGaD
Thalidomide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000236	CcSEcCtD
Thalidomide—Headache—Mycophenolic acid—systemic scleroderma	0.000109	0.000236	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—SMAD7—systemic scleroderma	0.000109	0.000582	CbGpPWpGaD
Thalidomide—Pharyngitis—Methotrexate—systemic scleroderma	0.000109	0.000235	CcSEcCtD
Thalidomide—NFKB1—Immune System—BLK—systemic scleroderma	0.000109	0.000582	CbGpPWpGaD
Thalidomide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000235	CcSEcCtD
Thalidomide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000235	CcSEcCtD
Thalidomide—Nausea—Leflunomide—systemic scleroderma	0.000108	0.000234	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CD40LG—systemic scleroderma	0.000108	0.00058	CbGpPWpGaD
Thalidomide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000108	0.000234	CcSEcCtD
Thalidomide—Vision blurred—Prednisone—systemic scleroderma	0.000107	0.000232	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—systemic scleroderma	0.000107	0.000232	CcSEcCtD
Thalidomide—Diarrhoea—Lisinopril—systemic scleroderma	0.000107	0.000232	CcSEcCtD
Thalidomide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000106	0.000229	CcSEcCtD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000106	0.000567	CbGpPWpGaD
Thalidomide—Visual impairment—Methotrexate—systemic scleroderma	0.000105	0.000228	CcSEcCtD
Thalidomide—Anaemia—Prednisone—systemic scleroderma	0.000105	0.000228	CcSEcCtD
Thalidomide—Agitation—Prednisone—systemic scleroderma	0.000105	0.000226	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	0.000104	0.00056	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TNFAIP3—systemic scleroderma	0.000104	0.000559	CbGpPWpGaD
Thalidomide—Angioedema—Prednisone—systemic scleroderma	0.000104	0.000225	CcSEcCtD
Thalidomide—Dizziness—Lisinopril—systemic scleroderma	0.000104	0.000224	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000103	0.000224	CcSEcCtD
Thalidomide—Nausea—Mycophenolic acid—systemic scleroderma	0.000103	0.000223	CcSEcCtD
Thalidomide—FGFR2—Immune System—BLK—systemic scleroderma	0.000103	0.000552	CbGpPWpGaD
Thalidomide—Malaise—Prednisone—systemic scleroderma	0.000103	0.000222	CcSEcCtD
Thalidomide—FGFR2—Disease—CD247—systemic scleroderma	0.000103	0.000551	CbGpPWpGaD
Thalidomide—Vertigo—Prednisone—systemic scleroderma	0.000102	0.000221	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—systemic scleroderma	0.000102	0.000221	CcSEcCtD
Thalidomide—Syncope—Prednisone—systemic scleroderma	0.000102	0.000221	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—systemic scleroderma	0.000102	0.000221	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000102	0.00022	CcSEcCtD
Thalidomide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000219	CcSEcCtD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000101	0.000541	CbGpPWpGaD
Thalidomide—Loss of consciousness—Prednisone—systemic scleroderma	0.0001	0.000217	CcSEcCtD
Thalidomide—Vomiting—Lisinopril—systemic scleroderma	9.95e-05	0.000215	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—systemic scleroderma	9.92e-05	0.000215	CcSEcCtD
Thalidomide—TNF—MAPK Signaling Pathway—TGFB1—systemic scleroderma	9.89e-05	0.00053	CbGpPWpGaD
Thalidomide—Immune system disorder—Methotrexate—systemic scleroderma	9.88e-05	0.000214	CcSEcCtD
Thalidomide—Rash—Lisinopril—systemic scleroderma	9.87e-05	0.000214	CcSEcCtD
Thalidomide—Convulsion—Prednisone—systemic scleroderma	9.87e-05	0.000214	CcSEcCtD
Thalidomide—Dermatitis—Lisinopril—systemic scleroderma	9.86e-05	0.000213	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—systemic scleroderma	9.86e-05	0.000213	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	9.84e-05	0.000528	CbGpPWpGaD
Thalidomide—Asthenia—Mycophenolate mofetil—systemic scleroderma	9.84e-05	0.000213	CcSEcCtD
Thalidomide—Hypertension—Prednisone—systemic scleroderma	9.84e-05	0.000213	CcSEcCtD
Thalidomide—Chills—Methotrexate—systemic scleroderma	9.81e-05	0.000212	CcSEcCtD
Thalidomide—Headache—Lisinopril—systemic scleroderma	9.81e-05	0.000212	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	9.75e-05	0.000523	CbGpPWpGaD
Thalidomide—Pruritus—Mycophenolate mofetil—systemic scleroderma	9.7e-05	0.00021	CcSEcCtD
Thalidomide—Myalgia—Prednisone—systemic scleroderma	9.7e-05	0.00021	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—systemic scleroderma	9.7e-05	0.00021	CcSEcCtD
Thalidomide—Anxiety—Prednisone—systemic scleroderma	9.67e-05	0.000209	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—systemic scleroderma	9.66e-05	0.000209	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	9.63e-05	0.000208	CcSEcCtD
Thalidomide—Discomfort—Prednisone—systemic scleroderma	9.58e-05	0.000207	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—systemic scleroderma	9.58e-05	0.000207	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—systemic scleroderma	9.52e-05	0.000206	CcSEcCtD
Thalidomide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	9.38e-05	0.000203	CcSEcCtD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	9.38e-05	0.000503	CbGpPWpGaD
Thalidomide—Dysgeusia—Methotrexate—systemic scleroderma	9.32e-05	0.000202	CcSEcCtD
Thalidomide—Nausea—Lisinopril—systemic scleroderma	9.3e-05	0.000201	CcSEcCtD
Thalidomide—Oedema—Prednisone—systemic scleroderma	9.3e-05	0.000201	CcSEcCtD
Thalidomide—Infection—Prednisone—systemic scleroderma	9.24e-05	0.0002	CcSEcCtD
Thalidomide—Back pain—Methotrexate—systemic scleroderma	9.21e-05	0.000199	CcSEcCtD
Thalidomide—Shock—Prednisone—systemic scleroderma	9.15e-05	0.000198	CcSEcCtD
Thalidomide—Nervous system disorder—Prednisone—systemic scleroderma	9.12e-05	0.000197	CcSEcCtD
Thalidomide—Tachycardia—Prednisone—systemic scleroderma	9.07e-05	0.000196	CcSEcCtD
Thalidomide—Dizziness—Mycophenolate mofetil—systemic scleroderma	9.07e-05	0.000196	CcSEcCtD
Thalidomide—Skin disorder—Prednisone—systemic scleroderma	9.03e-05	0.000195	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisone—systemic scleroderma	8.99e-05	0.000194	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—systemic scleroderma	8.97e-05	0.000194	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	8.92e-05	0.000479	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTLA4—systemic scleroderma	8.89e-05	0.000477	CbGpPWpGaD
Thalidomide—Anorexia—Prednisone—systemic scleroderma	8.86e-05	0.000192	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—RHOB—systemic scleroderma	8.85e-05	0.000475	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP2—systemic scleroderma	8.84e-05	0.000474	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Methotrexate—systemic scleroderma	8.83e-05	0.000191	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—systemic scleroderma	8.8e-05	0.00019	CcSEcCtD
Thalidomide—Vomiting—Mycophenolate mofetil—systemic scleroderma	8.72e-05	0.000189	CcSEcCtD
Thalidomide—Rash—Mycophenolate mofetil—systemic scleroderma	8.65e-05	0.000187	CcSEcCtD
Thalidomide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	8.64e-05	0.000187	CcSEcCtD
Thalidomide—Headache—Mycophenolate mofetil—systemic scleroderma	8.59e-05	0.000186	CcSEcCtD
Thalidomide—Malaise—Methotrexate—systemic scleroderma	8.59e-05	0.000186	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—systemic scleroderma	8.55e-05	0.000185	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—systemic scleroderma	8.52e-05	0.000184	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	8.47e-05	0.000183	CcSEcCtD
Thalidomide—FGFR2—Immune System—CTLA4—systemic scleroderma	8.43e-05	0.000452	CbGpPWpGaD
Thalidomide—Insomnia—Prednisone—systemic scleroderma	8.41e-05	0.000182	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—RHOB—systemic scleroderma	8.4e-05	0.000451	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HSPG2—systemic scleroderma	8.35e-05	0.000448	CbGpPWpGaD
Thalidomide—Paraesthesia—Prednisone—systemic scleroderma	8.35e-05	0.000181	CcSEcCtD
Thalidomide—Cough—Methotrexate—systemic scleroderma	8.31e-05	0.00018	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—systemic scleroderma	8.25e-05	0.000178	CcSEcCtD
Thalidomide—Dyspepsia—Prednisone—systemic scleroderma	8.18e-05	0.000177	CcSEcCtD
Thalidomide—Nausea—Mycophenolate mofetil—systemic scleroderma	8.15e-05	0.000176	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	8.11e-05	0.000435	CbGpPWpGaD
Thalidomide—Chest pain—Methotrexate—systemic scleroderma	8.11e-05	0.000175	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—systemic scleroderma	8.11e-05	0.000175	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—systemic scleroderma	8.11e-05	0.000175	CcSEcCtD
Thalidomide—Decreased appetite—Prednisone—systemic scleroderma	8.08e-05	0.000175	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—CSK—systemic scleroderma	8.06e-05	0.000432	CbGpPWpGaD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	8.05e-05	0.000174	CcSEcCtD
Thalidomide—Fatigue—Prednisone—systemic scleroderma	8.02e-05	0.000173	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—systemic scleroderma	8.01e-05	0.000173	CcSEcCtD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	8.01e-05	0.000429	CbGpPWpGaD
Thalidomide—Constipation—Prednisone—systemic scleroderma	7.95e-05	0.000172	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—HSPG2—systemic scleroderma	7.92e-05	0.000425	CbGpPWpGaD
Thalidomide—Confusional state—Methotrexate—systemic scleroderma	7.83e-05	0.00017	CcSEcCtD
Thalidomide—Infection—Methotrexate—systemic scleroderma	7.72e-05	0.000167	CcSEcCtD
Thalidomide—PTGS2—Disease—SMAD7—systemic scleroderma	7.7e-05	0.000413	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.67e-05	0.000412	CbGpPWpGaD
Thalidomide—Feeling abnormal—Prednisone—systemic scleroderma	7.66e-05	0.000166	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—CSK—systemic scleroderma	7.65e-05	0.00041	CbGpPWpGaD
Thalidomide—Nervous system disorder—Methotrexate—systemic scleroderma	7.62e-05	0.000165	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—systemic scleroderma	7.61e-05	0.000165	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—systemic scleroderma	7.6e-05	0.000164	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—systemic scleroderma	7.55e-05	0.000163	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—systemic scleroderma	7.51e-05	0.000163	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—systemic scleroderma	7.41e-05	0.00016	CcSEcCtD
Thalidomide—Urticaria—Prednisone—systemic scleroderma	7.39e-05	0.00016	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—systemic scleroderma	7.35e-05	0.000159	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—systemic scleroderma	7.35e-05	0.000159	CcSEcCtD
Thalidomide—NFKB1—Immune System—HLA-DQB1—systemic scleroderma	7.32e-05	0.000392	CbGpPWpGaD
Thalidomide—Hypotension—Methotrexate—systemic scleroderma	7.26e-05	0.000157	CcSEcCtD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.11e-05	0.000381	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	7.08e-05	0.000153	CcSEcCtD
Thalidomide—PTGS2—Disease—TGFBI—systemic scleroderma	7.04e-05	0.000378	CbGpPWpGaD
Thalidomide—Insomnia—Methotrexate—systemic scleroderma	7.03e-05	0.000152	CcSEcCtD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7e-05	0.000375	CbGpPWpGaD
Thalidomide—Paraesthesia—Methotrexate—systemic scleroderma	6.98e-05	0.000151	CcSEcCtD
Thalidomide—NFKB1—Immune System—IL1A—systemic scleroderma	6.95e-05	0.000373	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQB1—systemic scleroderma	6.94e-05	0.000372	CbGpPWpGaD
Thalidomide—Dyspnoea—Methotrexate—systemic scleroderma	6.93e-05	0.00015	CcSEcCtD
Thalidomide—NFKB1—Immune System—CD40LG—systemic scleroderma	6.91e-05	0.000371	CbGpPWpGaD
Thalidomide—Somnolence—Methotrexate—systemic scleroderma	6.91e-05	0.000149	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—systemic scleroderma	6.85e-05	0.000148	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—systemic scleroderma	6.84e-05	0.000148	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—systemic scleroderma	6.75e-05	0.000146	CcSEcCtD
Thalidomide—TNF—Developmental Biology—MMP2—systemic scleroderma	6.74e-05	0.000361	CbGpPWpGaD
Thalidomide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	6.71e-05	0.000145	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—systemic scleroderma	6.7e-05	0.000145	CcSEcCtD
Thalidomide—Asthenia—Prednisone—systemic scleroderma	6.67e-05	0.000144	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—MMP9—systemic scleroderma	6.64e-05	0.000356	CbGpPWpGaD
Thalidomide—Pain—Methotrexate—systemic scleroderma	6.64e-05	0.000144	CcSEcCtD
Thalidomide—FGFR2—Immune System—IL1A—systemic scleroderma	6.6e-05	0.000354	CbGpPWpGaD
Thalidomide—Pruritus—Prednisone—systemic scleroderma	6.58e-05	0.000142	CcSEcCtD
Thalidomide—FGFR2—Immune System—CD40LG—systemic scleroderma	6.56e-05	0.000352	CbGpPWpGaD
Thalidomide—Feeling abnormal—Methotrexate—systemic scleroderma	6.4e-05	0.000139	CcSEcCtD
Thalidomide—Diarrhoea—Prednisone—systemic scleroderma	6.36e-05	0.000138	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—systemic scleroderma	6.35e-05	0.000137	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—systemic scleroderma	6.17e-05	0.000134	CcSEcCtD
Thalidomide—Dizziness—Prednisone—systemic scleroderma	6.15e-05	0.000133	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—systemic scleroderma	6.14e-05	0.000133	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—systemic scleroderma	6.14e-05	0.000133	CcSEcCtD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.98e-05	0.000321	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—HSPG2—systemic scleroderma	5.93e-05	0.000318	CbGpPWpGaD
Thalidomide—Vomiting—Prednisone—systemic scleroderma	5.91e-05	0.000128	CcSEcCtD
Thalidomide—Rash—Prednisone—systemic scleroderma	5.86e-05	0.000127	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—systemic scleroderma	5.86e-05	0.000127	CcSEcCtD
Thalidomide—Headache—Prednisone—systemic scleroderma	5.82e-05	0.000126	CcSEcCtD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.82e-05	0.000312	CbGpPWpGaD
Thalidomide—Hypersensitivity—Methotrexate—systemic scleroderma	5.72e-05	0.000124	CcSEcCtD
Thalidomide—PTGS2—Disease—HSPG2—systemic scleroderma	5.62e-05	0.000301	CbGpPWpGaD
Thalidomide—Asthenia—Methotrexate—systemic scleroderma	5.57e-05	0.000121	CcSEcCtD
Thalidomide—Nausea—Prednisone—systemic scleroderma	5.52e-05	0.000119	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	5.52e-05	0.000296	CbGpPWpGaD
Thalidomide—Pruritus—Methotrexate—systemic scleroderma	5.5e-05	0.000119	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—TGFB1—systemic scleroderma	5.48e-05	0.000294	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CSK—systemic scleroderma	5.43e-05	0.000291	CbGpPWpGaD
Thalidomide—Diarrhoea—Methotrexate—systemic scleroderma	5.32e-05	0.000115	CcSEcCtD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.3e-05	0.000284	CbGpPWpGaD
Thalidomide—Dizziness—Methotrexate—systemic scleroderma	5.14e-05	0.000111	CcSEcCtD
Thalidomide—PTGS2—Disease—CD247—systemic scleroderma	5.1e-05	0.000274	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—systemic scleroderma	5.06e-05	0.000271	CbGpPWpGaD
Thalidomide—Vomiting—Methotrexate—systemic scleroderma	4.94e-05	0.000107	CcSEcCtD
Thalidomide—Rash—Methotrexate—systemic scleroderma	4.9e-05	0.000106	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—systemic scleroderma	4.89e-05	0.000106	CcSEcCtD
Thalidomide—Headache—Methotrexate—systemic scleroderma	4.87e-05	0.000105	CcSEcCtD
Thalidomide—PTGS2—Metabolism—HSPG2—systemic scleroderma	4.71e-05	0.000252	CbGpPWpGaD
Thalidomide—Nausea—Methotrexate—systemic scleroderma	4.62e-05	9.99e-05	CcSEcCtD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.53e-05	0.000243	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EDN1—systemic scleroderma	4.52e-05	0.000242	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CTGF—systemic scleroderma	4.49e-05	0.000241	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HSPG2—systemic scleroderma	4.43e-05	0.000238	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HSPG2—systemic scleroderma	4.42e-05	0.000237	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EDN1—systemic scleroderma	4.29e-05	0.00023	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HSPG2—systemic scleroderma	4.18e-05	0.000224	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—systemic scleroderma	4.17e-05	0.000224	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS3—systemic scleroderma	3.73e-05	0.0002	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—systemic scleroderma	3.63e-05	0.000194	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CTGF—systemic scleroderma	3.57e-05	0.000191	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—systemic scleroderma	3.44e-05	0.000184	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HSPG2—systemic scleroderma	3.42e-05	0.000183	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CTGF—systemic scleroderma	3.36e-05	0.00018	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CTGF—systemic scleroderma	3.35e-05	0.00018	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CTGF—systemic scleroderma	3.16e-05	0.00017	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HSPG2—systemic scleroderma	3.12e-05	0.000167	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—systemic scleroderma	3.09e-05	0.000166	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—systemic scleroderma	2.93e-05	0.000157	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—systemic scleroderma	2.75e-05	0.000148	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HSPG2—systemic scleroderma	2.66e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—systemic scleroderma	2.61e-05	0.00014	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CTGF—systemic scleroderma	2.59e-05	0.000139	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—systemic scleroderma	2.47e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CTGF—systemic scleroderma	2.36e-05	0.000127	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—systemic scleroderma	2.21e-05	0.000119	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—systemic scleroderma	2.1e-05	0.000112	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CTGF—systemic scleroderma	2.02e-05	0.000108	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—systemic scleroderma	1.96e-05	0.000105	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—systemic scleroderma	1.85e-05	9.94e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—systemic scleroderma	1.82e-05	9.77e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—systemic scleroderma	1.73e-05	9.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—systemic scleroderma	1.55e-05	8.32e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—systemic scleroderma	1.46e-05	7.84e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.46e-05	7.82e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—systemic scleroderma	1.38e-05	7.39e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—systemic scleroderma	1.23e-05	6.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—systemic scleroderma	1.13e-05	6.05e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—systemic scleroderma	1.03e-05	5.51e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—systemic scleroderma	8.78e-06	4.71e-05	CbGpPWpGaD
